Fauna Bio Incorporated

Fauna Bio Incorporated, based in Newark, CA, is an innovative AI-driven drug discovery company that leverages genetic data from mammals with extraordinary disease resistance, aiming to create new therapeutic opportunities for human health. With its proprietary Convergence platform, Fauna Bio seeks to replicate the unique metabolic adaptations of species such as the 13-lined ground squirrel and spiny mouse to identify novel drug targets across a range of diseases, tapping into a substantial market opportunity.

The company has formed significant partnerships, including a multi-year agreement with Eli Lilly to focus on drug discovery for obesity, and is actively engaged in research to understand human metabolism in space. Through collaborations with various academic institutions, Fauna Bio continues to explore the potential of extreme animal models to unlock groundbreaking insights into regeneration and resilience against diseases.

Generated from the website